Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Emil_D._Kakkis
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
rare diseases
|
| gptkbp:foundedYear |
2010
|
| gptkbp:founder |
gptkb:Emil_D._Kakkis
|
| gptkbp:headquartersLocation |
gptkb:Novato,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ultragenyx Pharmaceutical
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableEmployee |
gptkb:Emil_D._Kakkis
|
| gptkbp:numberOfEmployees |
over 1000
|
| gptkbp:product |
gptkb:Crysvita
gptkb:Dojolvi gptkb:Evkeeza gptkb:Mepsevii |
| gptkbp:publiclyTraded |
true
|
| gptkbp:specialty |
gene therapy
enzyme replacement therapies genetic metabolic diseases |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
RARE
|
| gptkbp:website |
https://www.ultragenyx.com/
|
| gptkbp:bfsParent |
gptkb:Clay_Siegall
|
| gptkbp:bfsLayer |
6
|